Display options
Cite
Arezzo JC, Rosenstock J, Lamoreaux L, et al. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008;8:33doi: 10.1186/1471-2377-8-33.
Arezzo, J. C., Rosenstock, J., Lamoreaux, L., & Pauer, L. (2008). Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC neurology, 833. https://doi.org/10.1186/1471-2377-8-33
Arezzo, Joseph C, et al. "Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial." BMC neurology vol. 8 (2008): 33. doi: https://doi.org/10.1186/1471-2377-8-33
Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008 Sep 16;8:33. doi: 10.1186/1471-2377-8-33. PMID: 18796160; PMCID: PMC2565674.
Copy Download .nbib Format: NLM
Share it on

BMC Neurol. 2008 Sep 16;8:33. doi: 10.1186/1471-2377-8-33.

Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial.

BMC neurology

Joseph C Arezzo, Julio Rosenstock, Linda Lamoreaux, Lynne Pauer

Affiliations

  1. Albert Einstein College of Medicine, New York, NY, USA. [email protected]

PMID: 18796160 PMCID: PMC2565674 DOI: 10.1186/1471-2377-8-33

Abstract

BACKGROUND: Recent consensus guidelines recommend pregabalin as a first-tier treatment for painful diabetic peripheral neuropathy (DPN). We evaluated the efficacy of pregabalin 600 mg/d (300 mg dosed BID) versus placebo for relieving DPN-associated neuropathic pain, and assessed its safety using objective measures of nerve conduction (NC).

METHODS: In this randomized, double-blind, placebo-controlled trial, the primary efficacy measure was endpoint mean pain score (MPS) from daily pain diaries (11-point scale). NC velocity and sensory and motor amplitudes were assessed at baseline, endpoint, and end of follow-up (2 weeks post-treatment). At each timepoint, the median-motor, median-sensory, ulnar-sensory, and peroneal-motor nerves were evaluated. Secondary efficacy measures included weekly MPS and proportion of responders (patients achieving >or=50% reduction in MPS from baseline to endpoint). After 1-weeks' dosage escalation, pregabalin-treated patients received 300 mg BID for 12 weeks.

RESULTS: Eighty-two patients received pregabalin and 85 placebo. Mean durations were 10 years for diabetes and approximately 5 years for painful DPN. Pregabalin-treated patients had lower MPS than controls (mean difference, -1.28; p <.001). For all four nerves, 95% CIs for median differences in amplitude and velocity from baseline to endpoint and baseline to follow-up included 0 (ie, no significant difference vs. placebo). Significant pain improvement among pregabalin-treated patients was evident at week 1 and sustained at every weekly timepoint. More pregabalin-treated patients (49%) than controls (23%) were responders (p <.001).

CONCLUSION: Pregabalin 600 mg/d (300 mg BID) effectively reduced pain, was well tolerated, and had no statistically significant or clinically meaningful effect on NC in patients with painful DPN.

References

  1. Am J Med. 1999 Aug 30;107(2B):9S-16S - PubMed
  2. Muscle Nerve. 1998 Nov;21(11):1368-73 - PubMed
  3. Eur J Neurol. 2006 Nov;13(11):1153-69 - PubMed
  4. Diabetes Metab Rev. 1995 Oct;11(3):193-225 - PubMed
  5. Eur J Pain. 2008 Feb;12(2):203-13 - PubMed
  6. Pain. 1987 Aug;30(2):191-197 - PubMed
  7. Mayo Clin Proc. 2006 Apr;81(4 Suppl):S12-25 - PubMed
  8. Diabetes Care. 2005 Apr;28(4):956-62 - PubMed
  9. Pain. 2004 Aug;110(3):628-638 - PubMed
  10. Neurology. 2004 Dec 14;63(11):2104-10 - PubMed
  11. J Pain Symptom Manage. 2005 Oct;30(4):374-85 - PubMed
  12. Pain. 2005 Jun;115(3):254-263 - PubMed
  13. Diabetes Care. 2005 Sep;28(9):2192-200 - PubMed
  14. Clin J Pain. 2006 Oct;22(8):681-5 - PubMed
  15. Drugs. 2004;64(24):2813-20; discussion 2821 - PubMed
  16. Neurology. 1992 Sep;42(9):1823-5 - PubMed
  17. Pain. 2004 May;109(1-2):26-35 - PubMed
  18. Neurology. 2003 Apr 22;60(8):1274-83 - PubMed
  19. Clin J Pain. 2002 Nov-Dec;18(6):350-4 - PubMed
  20. Diabetes Care. 2004 Jun;27(6):1458-86 - PubMed
  21. J Pain. 2005 Apr;6(4):253-60 - PubMed
  22. Curr Med Res Opin. 2006 Feb;22(2):375-84 - PubMed
  23. Neurology. 2004 Sep 28;63(6):959-65 - PubMed
  24. Br Med J (Clin Res Ed). 1988 May 21;296(6634):1454-6 - PubMed
  25. Diabetes Care. 1989 Oct;12(9):649-52 - PubMed
  26. Int Rev Neurobiol. 2002;50:229-55 - PubMed

Substances

MeSH terms

Publication Types